Genoa Ventures, led by founder and managing director Jenny Rooke, is carving out a niche investing in life sciences technology.
Why it matters: Eve as the drug development sector reels from looming pharma tariffs,Most Favored Nation threats and NIH grant pullbacks, Genoa companies may benefit from some tailwinds.
